Abound Wealth Management Supernus Pharmaceuticals, Inc. Transaction History
Abound Wealth Management
- $301 Billion
- Q3 2024
A detailed history of Abound Wealth Management transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Abound Wealth Management holds 6 shares of SUPN stock, worth $226. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6
Previous 12
50.0%
Holding current value
$226
Previous $321,000
41.43%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
263Shares Held
59.4MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$392 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$232 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$199 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$109 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$101 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.02B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...